Belluscura (BELL ) has appointed Brian Brown, who has over 25 years of experience in commercialising break-through new products, as its new Vice President of Engineering.
Belluscura, a medical device developer which is focused on developing lightweight and portable oxygen enrichment technology, said Mr Brown’s extensive knowledge in building a start-up medical device company will add to the company’s experienced management team.
Brown, who has over 25 years of experience in commercialising new products in hardware, software, and service delivery industries, built the start-up into a global supplier of diagnostic imaging medical devices where he held the titles of President and Chief Innovation Officer.
Brown, who is also a registered professional engineer and is the author of 17 US patents, stated: “It’s exciting to be part of a very talented Belluscura team. I look forward to helping Belluscura launch its breakthrough new technologies and change the face of patient care.”
Robert Rauker, CEO of Belluscura added: “We look forward to leveraging Brian’s background in new product commercialization. His knowledge in building a start-up medical device firm will add to our experienced management team. We’re excited to have Brian on board.”
In recent weeks, Belluscura announced that it had signed a new agreement with InnoMax Medical Technology that is expected to more than double its manufacturing capacity of its X-PLO2R® portable oxygen concentrator and accelerate its expansion into Asia and beyond.
The commercialisation and distribution in Asia are expected to occur no later than 1Q23 and Belluscura intends to manufacture both the company’s next generation X-PLO2R® oxygen concentrator and the next portable oxygen concentrator in its portfolio, the DISCOV-R™.
Belluscura’s devices are designed to address a market need: According to the World Health Organisation (“WHO”), over 1 billion people in the world suffer from chronic respiratory issues.
Overall, the global oxygen therapy market size is expected to grow at a significant CAGR of 10.12% from 2021 to 2026 to be worth $18.55 billion by 2026. The global portable oxygen concentrators market is forecast to be worth $2.76 billion by 2026 - that’s a CAGR of 14%.
In China alone, nearly 100 million people suffer from chronic obstructive pulmonary disease (“COPD”). This is 400% larger than the total US COPD population, and it is estimated to be the third leading cause of death in China.
Beyond this market, there are an estimated 50 million cases of COPD in India and over 5 million people in Japan suffering from COPD.
Follow News & Updates from Belluscura: